- Home
- DLNG vs CGTX Comparison
DLNG vs CGTX Comparison
Compare DLNG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLNG | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 132.4M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DLNG | CGTX |
|---|---|---|
| Price | $3.87 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 54.7K | ★ 938.8K |
| Earning Date | 03-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $158,275,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | ★ 4.34 | N/A |
| 52 Week Low | $3.18 | $0.22 |
| 52 Week High | $5.35 | $3.83 |
Technical Indicators
Market Signals| Indicator | DLNG | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 49.06 |
| Support Level | $3.70 | $1.37 |
| Resistance Level | $4.18 | $1.50 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 56.25 |
Price Performance
Historical ComparisonAbout DLNG Dynagas LNG Partners LP
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.